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Poster Session II S279There were 73 de novo and 5 secondary AML. Regarding cytogenet-
ics and molecular markers: 6 were in favourable, 29 in intermediate
and 38 in unfavourable group and we found 5 Flt3 mutated, 22 Flt3
ITD+, 4 MLL mutated, 13 Hoxa9 mutated, 10 Evi1 mutated, 34
Wt1 mutated and 17 NMP mutated, 11 patients were in the good
prognosis group and 61 in the poor prognosis group. At transplant,
42 patients were in CR1, 22 in.CR1 and 14 in progressive disease,
49 received a myelo-ablative and 29 a non myelo-ablative condition-
ing. As HSC source, 27 received PBSC, 46 bone marrow and 5 cord
blood cells.With amedian follow-up of 32months, the 3-years over-
all survival was 45%612 with no significant impact of age, FAB clas-
sification, kind of AML (de novo vs secondary), HSC source (PBSC
vs BM), Flt3, MLL, HoxA9, NMP and WT1 mutations. We found
a difference of survival but not reaching the significance for Flt3 ITD
[27.5% 620 (mutated)vs 52% 612 (non mutated), p5 0.09] and
a significant difference of survival for Evi1 [48.5%614 (non mu-
tated) vs 22.5% 626 (mutated), p5 0.04]. We also showed a differ-
ence of survival not reaching the significance according to
cytogenetics with 83%630 for favourable, 53%620 for intermesiate
and 28%616 for unfavourable although we observed a very signifi-
cant difference of OS according to the new prognosis classification
between the good prognosis group with 81%624 and the poor prog-
nosis group with 38%614 (p5 0.04). In addition, we found a signif-
icant better survival for patients in 1st CR (60%616) vs.CR1
(31%622) or in progressive disease (24%622)(p5 0.009) and a sig-
nificant difference of survival according to conditioning with
54%616 for myelo-abative vs 11%618 for RIC (p\0.0001).The
multivariate analysis showed a significant impact on OS of the new
prognosis classification [HR5 3.62 [95%CI 2.89-4.35] (p5 0.03)],
disease status at transplant [HR5 151 [95%CI 1.28-1.74]
(p5 0.07)], kind of conditioning [HR5 0.32 [95%CI 0-0.7]
(p5 0.003)], Evi1 [HR5 0.33[95%CI 0-0.8] (p5 0.02)] and Flt3
ITD [HR5 0.43 [95%CI 0.07-0.78] (p5 0.02)].
The OS after allogeneic HSCT remains very poor for patients
having Evi1 mutation and Flt3ITD for whom it is fundamental to
propose new strategy of allogeneic HSCT in 1st CR as for example
allotransplant after FLAMSA regimen or haplo-identical allogeneic
HSCT.326
CD3 CELL DOSE AND OUTCOME AFTER ALLOGENEIC STEM CELL TRANS-
PLANTATION
Farhan, S., Mckinnon, R., Fortney, C., Divine, G., Janakiraman, N.
Henry Ford Health System, Detroit, MI
Background: Stem cell dose for transplant is determined by CD34
althoughT cells are co-infused. A clear association of CD3with clin-
ical outcome is not established. The dose of CD3 is usually not taken
into consideration except in T cell depleted transplantation. We did
a retrospective analysis to study the effect of CD3cell infused on
mortality, relapse, graft versus host disease (GVHD) and engraft-
ment.
Methods: 161 patients with allogeneic stem cell transplantation, pe-
ripheral (PSCT) and marrow, were identified from the BMT Regis-
try at Henry Ford Health System between 1999 and 2009. We
classified disease risk into 2 categories; Low risk which includes acute
leukemia and lymphoma in first complete remission or chronic my-
eloid leukemia in chronic phase. All others were considered as high
risk disease. Engraftment is defined as absolute Neutrophil count
(ANC) of 500/mm3and platelets as 20,000/mm3 per CIBMTR cri-
teria. Acute GVHD was graded according to Glucksberg system.
Results: Among 161 patients, 137 patients (85%) had PSCT and 24
(15%) had marrow transplant. Mean age was 47.72 (19-71). Patients
with high risk diseasewere 137 (85%), low risk diseasewere 24 (15%).
147 (91%) received myeloablative regimens while 14 (9%) received
a non-myeloablative one. Source of transplant was related in 117 pa-
tients (73%), unrelated in 44 (27%). 120 patients (75%) had a good
match. Mean dose of CD34 infused was 5.75106/kg (1-22.3) while
mean for CD3 infused was 1.23108/kg (0-13.4). There was a statis-
tically significant adverse correlation betweenCD3 infused and over-
all survival (p5 0.013). This was true even when adjusted for age,
match status and disease risk (HR5 1.167,p5 0.010). We did not
find association between CD3 infused and grade II-IV GVHD orrelapse. There was very small negative correlation between CD3 in-
fused and days to ANC 500 (r5 -0.14, p5 0.089). After adjustment
for the few outliers, the partial correlation was -0.15, p5 0.086.
There was also a modest positive correlation with Platelet 20000,
r5 0.36, p\0.001. After adjustment, the correlation was 0.37,
p\0.001.
Conclusion: In this small group of 161 allo-stem cell transplant, we
found that the dose of CD3 infused significantly affected the out-
come by decreasing survival and modestly affecting days to engraft-
ment. This supports the need to monitor CD3 and to be aware of it
when deciding CD34 dose to be infused. Since this is a small group,
further studies involving larger cohort of patients are needed.327
APHERESIS AND TRANSPLANT OF HEMATOPOIETIC PROGENITOR CELLS
(HPC) FROM ALLOGENEIC DONORS $60 YEARS OF AGE
Janssen, W.E., Ayala, E., Field, T., Kharfan-Dabaja, M., Ochoa, L.,
Rahn, D., Hackett, M., Coyle, D., Anasetti, C., Fernandez, H.F. Moffitt
Cancer Center, Tampa, FL
There has been reluctance to collect apheresis HPC allografts
from donors of age 60 or greater. This is predicated on concern
over relative frailty, poor venous access, reduced potential for
HPC mobilization, and reduced potential for stable engraftment of
HPC transplant. We have expanded our transplant eligibility into
patients beyond the age of 60, with the concomitant acceptance of
sibling donors of similar age. Herein we review 104 consecutive sib-
ling donors, 20 of whom were of age$60 years at the time of collec-
tion. All donors were collected beginning on day 5 of 10mcg/Kg/day
of G-CSF mobilization. Apheresis was performed using Caridian
Spectra instruments, and the volume of blood processedwas adjusted
to target a CD34 dose of 5-10million per Kg of recipient weight.We
have compared these two groups of donors for total blood volumes
(TBV) processed, CD34 cells recovered per Kg of recipient weight,
and CD34 cells recovered per TBV apheresed, using Student’s T-
test. Comparison of rates of failure to recover 5 million CD34/Kg-
recipient, requiring greater than one collection, requiring a catheter,
and of having a grade 3 or 4 reaction to apheresis were performed us-
ing Fisher’s exact test, and comparison of engraftment rates was per-
formed using the log-rank statistic. Our findings are presented in the
table. These results demonstrate that donors of age $60 years may
be successfully collected by apheresis following G-CSF mobiliza-
tion, and that the resultant grafts can be expected to produce success-
ful transplants. There no greater rate of toxicity or need for catheter
insertion associated with the collections in the older age group.
There was, however, a clear trend to reduced mobilization of
CD34+ cells, as reflected in an apparent need for more collections,
and statistically fewer CD34+ cells per blood volume leukopheresed.
In spite of this, sufficient cells to produce functional grafts were col-
lected from all donors, although a limited number of donors in both
age categories failed to collect a full 5e + 6 CD34/Kg. We conclude
that in the context of an aging demographic, allograft donors of age
$60 may be successfully employed for HPC collection. Further, we
propose that the application of plerixafor in $60 year old donors
should be investigated in the context of a growing need to collect al-
lografts from donors in this age group.Age\60 Age. 60
(n5 86) (n5 20) pBlood volumes (Mean6 Std) 5.06 3.3 6.16 3.1 0.17
CD34/RecipKg E6 (Mean6 Std) 8.36 3.1 5.86 1.7 0.001
CD34/Blood vol E7. (Mean6 Std) 18.76 11.8 11.06 7.6 0.006
\ 5E6 CD34/Kg Collected (n) 6 3 0.25
. 1 collection (n) 15 7 0.087
Catheter required (n) 25 6 0.59
Grade 31 pheresis complications 2 3 0.047
ANC500 Median days (Min-Max) 16 (10-28) 16 (13-75) 0.14
Plt20 K Median days (Min-Max) 16 (8-77) 16 (13-89) 0.30
